Johnson & Johnson announced an investment of more than $2B to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. “The new facility will expand production of the company’s portfolio and pipeline of innovative biologics in support of Johnson & Johnson’s broader plan to advance more than 70 novel therapy and product expansion filings and launches by the end of the decade… The new facility will expand production of Johnson & Johnson’s innovative biologic medicines in areas including oncology, immunology, and neuroscience, with the latest technology focused on enabling efficient manufacturing operations. When fully operational, the site will employ approximately 420 full-time, highly skilled employees. Construction is anticipated to begin in the first half of 2025,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson files for FDA approval of Darzalex Faspro-based regimen
- Johnson & Johnson rolls out new TECNIS Odyssey
- Johnson & Johnson reports results from Phase 3 CARTITUDE-4 study
- J&J says Phase 3 CEPHEUS study meets primary endpoint
- Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study